Downregulated Acetyl-CoA Acyltransferase 2 Promoted the Progression of Hepatocellular Carcinoma and Participated in the Formation of Immunosuppressive Microenvironment

References

• Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(5):541–565. doi:10.6004/jnccn.2021.0022
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervas-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242. doi:10.1038/nri3405
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III trial. J Clin Oncol. 2020;38(3):193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang C, Liu W, et al. Long noncoding RNA LINC01234 promotes hepatocellular carcinoma progression through orchestrating aspartate metabolic reprogramming. Mol Ther. 2022;30(6):2354–2369. doi:10.1016/j.ymthe.2022.02.020
   PubMed Web of Science ®Google Scholar
• Hu C, Xin Z, Sun X, et al. Activation of ACLY by SEC63 deploys metabolic reprogramming to facilitate hepatocellular carcinoma metastasis upon endoplasmic reticulum stress. J Exp Clin Cancer Res. 2023;42(1):108. doi:10.1186/s13046-023-02656-7
   PubMed Web of Science ®Google Scholar
• Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol Cell. 2020;78(6):1019–1033. doi:10.1016/j.molcel.2020.05.034
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200. doi:10.1126/sciadv.1600200
   PubMed Web of Science ®Google Scholar
• Kodama T, Bard-Chapeau EA, Newberg JY, et al. Two-step forward genetic screen in mice identifies ral GTPase-activating proteins as suppressors of hepatocellular carcinoma. Gastroenterology. 2016;151(2):324–337.e12. doi:10.1053/j.gastro.2016.04.040
   PubMed Web of Science ®Google Scholar
• Miltiadou D, Hager-Theodorides AL, Symeou S, et al. Variants in the 3’ untranslated region of the ovine acetyl-coenzyme A acyltransferase 2 gene are associated with dairy traits and exhibit differential allelic expression. J Dairy Sci. 2017;100(8):6285–6297. doi:10.3168/jds.2016-12326
   PubMed Web of Science ®Google Scholar
• Agarwal N, Iyer D, Gabbi C, et al. HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXRalpha and PPARalpha dysregulation: implications for HIV-specific pathogenesis of NAFLD. Sci Rep. 2017;7(1):13362. doi:10.1038/s41598-017-13835-w
   PubMedGoogle Scholar
• Lei X, Xu Q, Li C, et al. Egr1 confers protection against Acetaminophen-induced hepatotoxicity via transcriptional upregulating of Acaa2. Int J Biol Sci. 2022;18(9):3800–3817. doi:10.7150/ijbs.71781
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202. doi:10.1093/bioinformatics/btz210
   PubMed Web of Science ®Google Scholar
• Lu X, Jiang L, Zhang L, et al. Immune signature-based subtypes of cervical squamous cell carcinoma tightly associated with human papillomavirus type 16 expression, molecular features, and clinical outcome. Neoplasia. 2019;21(6):591–601. doi:10.1016/j.neo.2019.04.003
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Reig M, Celsa C, et al. First-line immune checkpoint inhibitor-based sequential therapies for advanced hepatocellular carcinoma: rationale for future trials. Liver Cancer. 2022;11(1):75–84. doi:10.1159/000520278
   PubMedGoogle Scholar
• Sparchez Z, Radu P, Bartos A, et al. Combined treatments in hepatocellular carcinoma: time to put them in the guidelines? World J Gastrointest Oncol. 2021;13(12):1896–1918. doi:10.4251/wjgo.v13.i12.1896
   PubMed Web of Science ®Google Scholar
• Hu B, Yu M, Ma X, et al. Interferon-A potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discov. 2022;12(7):1718–1741. doi:10.1158/2159-8290.CD-21-1022
   PubMed Web of Science ®Google Scholar
• Xia Y, Tang W, Qian X, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, Phase II clinical trial. J Immunother Cancer. 2022;10(4):e004656. doi:10.1136/jitc-2022-004656
   PubMed Web of Science ®Google Scholar
• Petitprez F, Meylan M, de Reynies A, Sautes-Fridman C, Fridman WH. The tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol. 2020;11:784. doi:10.3389/fimmu.2020.00784
   PubMed Web of Science ®Google Scholar
• Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30(1):36–50. doi:10.1016/j.cmet.2019.06.001
   PubMed Web of Science ®Google Scholar
• Liu X, Hartman CL, Li L, et al. Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy. Sci Transl Med. 2021;13(587). doi:10.1126/scitranslmed.aaz6314
   Web of Science ®Google Scholar
• Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell. 2019;179(2):561–577 e522. doi:10.1016/j.cell.2019.08.052
   PubMed Web of Science ®Google Scholar
• Sun R, Zhang Z, Bao R, et al. Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis. J Hepatol. 2022;77(2):453–466. doi:10.1016/j.jhep.2022.02.030
   PubMed Web of Science ®Google Scholar
• Wang N, Liu W, Zheng Y, et al. CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-kappaB/SOX4 signaling. Cell Death Dis. 2018;9(9):880. doi:10.1038/s41419-018-0876-3
   PubMed Web of Science ®Google Scholar
• Ogawa R, Yamamoto T, Hirai H, et al. Loss of SMAD4 promotes colorectal cancer progression by recruiting tumor-associated neutrophils via the CXCL1/8-CXCR2 axis. Clin Cancer Res. 2019;25(9):2887–2899. doi:10.1158/1078-0432.CCR-18-3684
   PubMed Web of Science ®Google Scholar
• Liu ZY, Zheng M, Li YM, et al. RIP3 promotes colitis-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression. Theranostics. 2019;9(12):3659–3673. doi:10.7150/thno.32126
   PubMed Web of Science ®Google Scholar
• Alannan M, Fayyad-Kazan H, Trézéguet V, et al. Targeting lipid metabolism in liver cancer. Biochemistry. 2020;59(41):3951–3964. doi:10.1021/acs.biochem.0c00477
   PubMed Web of Science ®Google Scholar
• de Galarreta M R, Bresnahan E, Molina-Sanchez P, et al. Beta-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124–1141. doi:10.1158/2159-8290.CD-19-0074
   PubMed Web of Science ®Google Scholar